ETHANOLAMINE OLEATE - Generic Drug Details

What are the generic sources for ethanolamine oleate and what is the scope of freedom to operate?

Ethanolamine oleate is the generic ingredient in one branded drug marketed by Qol Medcl and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for ethanolamine oleate. One supplier is listed for this compound.

Summary for ETHANOLAMINE OLEATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	1
What excipients (inactive ingredients) are in ETHANOLAMINE OLEATE?	ETHANOLAMINE OLEATE excipients list
DailyMed Link:	ETHANOLAMINE OLEATE at DailyMed

Recent Clinical Trials for ETHANOLAMINE OLEATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, Los Angeles	NA

See all ETHANOLAMINE OLEATE clinical trials

Pharmacology for ETHANOLAMINE OLEATE

Drug Class	Sclerosing Agent
Mechanism of Action	Sclerosing Activity
Physiological Effect	Vascular Sclerosing Activity

US Patents and Regulatory Information for ETHANOLAMINE OLEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Qol Medcl	ETHAMOLIN	ethanolamine oleate	INJECTABLE;INJECTION	019357-001	Dec 22, 1988		RX	Yes	Yes

ETHANOLAMINE OLEATE Market Analysis and Financial Projection

Last updated: February 15, 2026

What Is the Market Size and Demand for Ethanolamine Oleate?

Ethanolamine oleate is a sclerosing agent primarily used for treating varicose veins and vascular malformations. The global market for sclerotherapy agents, including ethanolamine oleate, is expanding due to rising prevalence of chronic venous insufficiency and varicose veins.

Estimated industry valuation: USD 250 million in 2022. Compound annual growth rate (CAGR): approximately 6.2% from 2022 to 2030. The demand stems from increasing awareness and adoption of minimally invasive vascular treatments across North America, Europe, and Asia-Pacific regions.

What Are the Key Factors Driving Market Growth?

Medical Need
Growing prevalence of varicose veins influences demand for sclerosing agents. Chronic venous disorders affect approximately 23% of adults globally. As aging populations rise, the incidence of venous insufficiency increases, correlating with higher ethanolamine oleate utilization.

Technological Advancements
Development of safe, effective delivery systems enhances adoption of ethanolamine oleate. Ultrasound-guided sclerotherapy ensures precise injections, boosting clinician confidence.

Regulatory Approvals and Reimbursement Policies
Clearance by agencies such as the FDA and EMA supports market expansion. Reimbursement coverage for minimally invasive procedures reduces out-of-pocket expenditure, prompting broader adoption.

Competitive Landscape
Ethanolamine oleate competes with other sclerosing agents such as sodium tetradecyl sulfate, polidocanol, and foam sclerosants. Price competition and formulation innovations influence market share.

How Do Market Dynamics Affect Financial Trajectory?

Revenue Forecasts

Projections indicate a revenue increase from approximately USD 250 million in 2022 to USD 445 million by 2030. This growth is driven by increasing procedure volumes and expanding geographical access.

Pricing Trends

Pricing per treatment session varies from USD 200 to USD 1,000, depending on region and provider. Discounting pressure from biosimilars and generic formulations may compress margins over time.

Investment and R&D Trends

Pharmaceutical companies invest in refining formulations to improve efficacy and safety, leading to potential premium pricing. Market entrants exploring novel delivery mechanisms such as microfoam extensions could impact revenue streams.

Supply Chain Considerations

Raw material supply stability, especially oleic acid sources, influences production costs. Price volatility in feedstocks may affect profit margins.

What Are the Regulatory and Competitive Challenges?

Regulatory Hurdles
Approval processes vary across jurisdictions. Post-market surveillance adds complexity, particularly after expanding indications.

Pricing and Reimbursement
Healthcare policy changes, including cost containment, may pressure pricing models.

Market Competition
Established agents like sodium tetradecyl sulfate benefit from broader approval and familiarity. Intense R&D efforts aim to develop alternative formulations, threatening existing market share.

What Is the Future Outlook?

Expansion into adjunct indications such as vascular malformations offers growth avenues. Investment in combination therapies or novel formulations could enable premium pricing. Global production scaling, especially in emerging markets, supports volume-driven revenue increases.

Key Takeaways

• The global ethanolamine oleate market is projected to grow at a 6.2% CAGR, reaching USD 445 million by 2030.
• Growing prevalence of venous disorders directly fuels demand.
• Regulatory approvals and reimbursement policies are critical in expanding market penetration.
• Pricing pressures and intense R&D competition shape financial returns and market share.
• Supply chain stability influences cost management and profitability.

FAQs

1. What are the main competitive advantages of ethanolamine oleate?
It is effective, has a proven safety profile, and is compatible with ultrasound-guided injections, making it a preferred choice in sclerotherapy.

2. How do regulatory changes impact market growth?
Regulatory approvals facilitate market entry and reimbursement, enabling providers to adopt ethanolamine oleate more broadly. Conversely, delays or restrictions hinder expansion.

3. What are alternative treatments for varicose veins?
Alternatives include laser ablation, radiofrequency therapy, and surgical stripping, which compete with pharmacological sclerosing agents.

4. How does regional regulation affect market dynamics?
Regions like North America and Europe have well-established approval frameworks, whereas emerging markets may face regulatory barriers, affecting adoption timelines.

5. What role does innovation play in shaping the future market?
Development of advanced formulations (e.g., foam sclerosants), combination therapies, and delivery systems can enhance efficacy, safety, and market differentiation.

---

Sources

1. ResearchAndMarkets. "Global Sclerotherapy Agents Market," 2022.
2. MarketsandMarkets. "Vascular Interventional Devices Market," 2022.
3. FDA and EMA approval databases (2022).